About TransCon CNP TransCon CNP (navepegritide) is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed for continuous inhibition of the overactive FGFR3 pathway in achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body
- Impact on blood sugar levels: MOTS-c has been shown to influence glucose metabolism
Pay attention to signs of a possible infection, such as worsening pain, warmth, or pus, or the symptoms of an allergic reaction, like hives, difficulty breathing, or swelling of the face and throat
However, their anti-inflammatory effects are often inferior to direct supplementation of EPA/DHA due to the limited conversion efficiency (37)
Practical Takeaways For clinicians and informed consumers, several conclusions stand out: GHK-Cu is one of the most extensively studied copper peptides
Find out more about sleep and arthritis